May 17, 2020

Athenahealth, Inc to buy Epocrates

mobile health pioneer
point-of-care medical application
Al
Admin
2 min
Athenahealth, Inc to buy Epocrates
Athehealth, Inc has signed definitive agreement to buy Epocrates, Inc. a mobile health pioneer widely recognized for developing the most-widely adopted...

Athehealth, Inc  has signed definitive agreement to buy Epocrates, Inc. a mobile health pioneer widely recognized for developing the most-widely adopted point-of-care medical application among the U.S. physicians. 

The board of directors of each of athenahealth and Epocrates has agreed to a price of $11.75 per share, in cash, for an aggregate purchase price of approximately $293 million.

The purchase price represents a 22 percent premium over the closing price per share of Epocrates on NASDAQ on Friday, January 4, 2013.

This is an all-cash offer for all the outstanding shares of Epocrates’ common stock. Athenahealth aims to finance this acquisition using available cash and funds available from its existing credit facility.

The closing of the transaction is subject to the approval of Epocrates shareholders and other customary closing conditions and is presently expected to occur early in the second quarter of 2013.

The Epocrates shareholders representing approximately 17.5% of the outstanding common stock have agreed to vote their shares in favor of the transaction.

With the acquisition of Epocrates, Athenahealth believes it will be able to better serve an expanded network of providers. 

The company also plans to build upon Epocrates’ success to date in transforming the way physicians access and engage with clinical information, with each other and with their patients.

Athenahealth, Inc is a provider of cloud-based electronic health record, practice management and care coordination services to medical groups and health systems. 

Share article

Jun 15, 2021

 NHS trials test that predicts sepsis 3 days in advance 

sepsis
MachineLearning
clinicaltrial
blooddisorder
2 min
Queen Alexandra Hospital is trialling a new sepsis test by Presymptom Health that uses machine learning to detect the onset of the disease

A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England. 

Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year. 

The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time. 

From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.

Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction. 

Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.

The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years. 

If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.

Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”

Share article